article thumbnail

CHMP meeting highlights: January 2024

European Pharmaceutical Review

Ryzneuta (efbemalenograstim alfa) received a positive opinion from the CHMP as a medicine to reduce the duration of neutropenia and the incidence of febrile neutropenia due to chemotherapy. Additionally, a positive opinion for Niapelf (paliperidone), a generic medicine for schizophrenia was adopted in the meeting.

article thumbnail

CHMP meeting highlights: April 2024

European Pharmaceutical Review

If approved, fruquintinib could provide a new oral, chemotherapy-free option as the first and only selective inhibitor of all three vascular endothelial growth factor receptors (VEGFR) receptors approved in the EU for this disease, according to Takeda. This covers paediatric plaque psoriasis, psoriatic arthritis and Crohn’s disease.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Rebranded Servier eyes €3bn in cancer drug sales by 2030

pharmaphorum

The latter brought in acute myeloid leukaemia (AML) and cholangiocarcinoma therapy Tibsovo (ivosidenib), which was approved as a first-line therapy for AML last year in combination with Bristol-Myers Squibb’s chemotherapy Vidaza (azacitidine), dramatically expanding the eligible patient population for the drug.

article thumbnail

CHMP meeting highlights – March 2023

European Pharmaceutical Review

The committee recommended granting a paediatric-use marketing authorisation (PUMA) for Pedmarqsi (sodium thiosulfate) for preventing ototoxicity induced by cisplatin chemotherapy. Ototoxicity is the development of hearing or balance problems due to a medicine. Cisplatin is a chemotherapy used to treat several types of cancer.

article thumbnail

CHMP meeting highlights – December 2022

European Pharmaceutical Review

The group adopted a positive opinion for Tremelimumab AstraZeneca (tremelimumab), to treat metastatic non-small cell lung cancer (NSCLC) in combination with Imfinzi (durvalumab) and platinum-based chemotherapy. This rare genetic disorder causes muscle weakness and is often fatal.

article thumbnail

How to Avoid Nausea After Eating

BuzzRx

However, triggers outside the digestive system can also result in nausea or vomiting, such as pregnancy-associated nausea (morning sickness), chemotherapy-associated nausea, and nausea caused by motion sickness, inner ear problems, migraine headaches, head injuries, brain infections, or tumors. Cannabinoids Examples: Nabilone.